Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study
Kimberly R. Kalli(Mayo Clinic), Keith L. Knutson(WinnMed), Amy C. Degnim(Mayo Clinic in Arizona), Allan B. Dietz(Mayo Clinic), Courtney L. Erskine(Mayo Clinic), James Krempski(University of North Carolina at Chapel Hill), Timothy J. Hobday(Mayo Clinic), Vera J. Suman(Mayo Clinic in Arizona), Linda M. Benson(Mayo Clinic), Matthew S. Block(Mayo Clinic in Arizona), Douglas Padley(Mayo Clinic), Lynn C. Hartmann(Mayo Clinic)
Cited by 0
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
|Journal of Clinical Oncology|2017|411